The mortality rate from cervix uteri malignant neoplasms in Japan has been forecasted to remain relatively stable from 2024 to 2027 at 4.6 deaths per hundred thousand women, before a slight increase to 4.7 in 2028. The value in 2023 stood at 4.5, indicating a consistent, albeit very mild, upward trend in mortality over the forecast period. This indicates an anticipated annual increase of about 0.5% from 2023 to 2028.
Future trends to watch for include potential advancements in medical technology and screening programs that could impact these mortality rates. Additionally, public health initiatives focusing on HPV vaccination and cervical cancer awareness could play a significant role in altering future projections.
